All our company updates, noteworthy news and press releases from us/our partners can be found below:

Licensing of Formulation Technology and Expand Collaboration with Satellos Bioscience Inc

October 6th, 2022

Satellos and NW PharmaTech have today established a joint venture company, NW Micelle Therapeutics Inc. for the purpose of developing an oral formulation of cannabidiol for the treatment of insomnia and other indications in the mental health sphere.

NW PharmaTech will arrange for and provide the funding required by the JV for the development of formulations, already underway at University of Toronto. AmpB Tech, a wholly owned subsidiary of Satellos, will license certain rights in its patent protected drug transport technology, OralTransTM, to the JV for use in developing the CBD formulations.


Update on Joint Development Initiative with Satellos Bioscience Inc

March 11th, 2022

Satellos and NW PharmaTech Limited are pleased to announce further developments in their joint development initiative which aims to develop products for the market for sleep disorders.

In furtherance of the Initiative, the parties intend to create a joint venture corporation  that will focus on the invention, development and scientific validation of oral formulations of cannabidiol-based (“CBD”) sleep aids targeted at the market for sleep disorders. Subject to the completion of negotiations, Satellos, through its wholly-owned subsidiary, Amphotericin B Technologies Inc., will license OralTransTM to the Joint Venture and NW PharamTech shall provide all funding. The parties hope to finalize the terms of the Joint Venture in the coming weeks.


Joint Development Agreement with Satellos Bioscience Inc for Oral CBD

August 18th, 2021

Satellos Bioscience Inc., formerly iCo Therapeutics, Inc., and NW PharmaTech Limited announced today that Amphotericin B Technologies, Inc., a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology, has entered into a Joint Development Agreement with NW PharmaTech to develop an oral formulation of cannabidiol (“CBD”). Oral CBD will initially target the global market for sleep aids, estimated at $3 billion in 2020. NW PharmaTech has agreed to provide an up-front payment and fund development costs of the formulation and testing for safety, toxicity and pharmacokinetics.



0203 693 3791


Beaufort Gardens
London SW3 1PW
United Kingdom